Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 1,310,000 shares, an increase of 22.4% from the March 15th total of 1,070,000 shares. Based on an average daily volume of 115,000 shares, the short-interest ratio is presently 11.4 days. Approximately 16.7% of the shares of the company are short sold.

Karyopharm Therapeutics Stock Performance

KPTI traded up $0.45 during midday trading on Monday, hitting $5.40. The company had a trading volume of 81,398 shares, compared to its average volume of 81,822. Karyopharm Therapeutics has a twelve month low of $3.51 and a twelve month high of $18.00. The firm’s 50-day simple moving average is $6.24 and its 200-day simple moving average is $9.63. The company has a market capitalization of $46.28 million, a PE ratio of -5.29 and a beta of 0.58.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) EPS for the quarter, topping analysts’ consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. As a group, sell-side analysts anticipate that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Velan Capital Investment Management LP bought a new position in Karyopharm Therapeutics during the fourth quarter worth about $27,000. Focus Partners Wealth bought a new position in shares of Karyopharm Therapeutics during the 4th quarter valued at about $31,000. TD Waterhouse Canada Inc. acquired a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $32,000. Two Sigma Advisers LP increased its stake in Karyopharm Therapeutics by 145.5% during the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after purchasing an additional 45,400 shares in the last quarter. Finally, Opti Capital Management LP acquired a new stake in Karyopharm Therapeutics during the 4th quarter worth approximately $85,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Robert W. Baird lowered their price target on Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. HC Wainwright raised their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, February 26th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $45.00 price target on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $57.50.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).